Stockscreener 앱 받기
31.95
3.42%
-1.13
전일 마감가:
$33.08
열려 있는:
$32.93
하루 거래량:
410.62K
Relative Volume:
0.87
시가총액:
$1.63B
수익:
$413.05M
순이익/손실:
$-27.67M
주가수익비율:
-56.95
EPS:
-0.561
순현금흐름:
$-30.75M
1주 성능:
-1.69%
1개월 성능:
+14.52%
6개월 성능:
-3.18%
1년 성능:
-9.87%
1일 변동 폭
$31.78
$32.97
1주일 범위
$31.78
$34.01
52주 변동 폭
$27.55
$40.71
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
31.95 | 1.63B | 413.05M | -27.67M | -30.75M | -0.561 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-07 | 업그레이드 | UBS | Sell → Buy |
| 2025-10-31 | 개시 | Wells Fargo | Overweight |
| 2025-09-18 | 재개 | Guggenheim | Neutral |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-05-27 | 개시 | Deutsche Bank | Buy |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-10-24 | 개시 | UBS | Sell |
| 2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
IMCR News | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
Is it a good idea to invest in Immunocore stock right now? - MSN
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - TradingView
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - TradingView
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - TradingView
Is it a Good Idea to Invest in Immunocore Stock Right Now? - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up - TradingView
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - TradingView
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - TradingView
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - TradingView
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - TradingView
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - TradingView
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - GlobeNewswire Inc.
Immunocore reports Phase 1 data for melanoma drug brenetafusp - Investing.com
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study - TradingView
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - TradingView
IMCRImmunocore Holdings plc ADR Stock Price and Quote - Finviz
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Wall Street analysts think Immunocore (IMCR) could surge 111.53%: Read this before placing a bet - MSN
69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR) - Stock Titan
Here's Why You Should Add Altimmune Stock to Your Portfolio Now - TradingView
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet - Yahoo Finance
Immunocore Holdings (NASDAQ: IMCR) plans 65,000 ADR cashless sale - Stock Titan
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - TradingView
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - TradingView
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - TradingView
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - TradingView
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention - TradingView
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - TradingView
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - TradingView
T. Rowe Price (IMCR) holds 1.89M ADRs, files Schedule 13G/A amendment - Stock Titan
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):